Given my left‑leg swelling without confirmed deep‑vein thrombosis and a family history of clotting disorders, including a relative with Factor V Leiden, what genetic tests should I undergo to evaluate for inherited thrombophilia?

Genetic Testing Recommendation for Thrombophilia

Based on your left leg swelling without confirmed clot and a family history of Factor V Leiden, you do NOT currently meet criteria for routine genetic testing according to the most recent 2025 ACMG guidelines, unless specific high-risk circumstances apply.

When Genetic Testing IS Recommended

The 2025 ACMG technical standard 111 provides clear criteria for thrombophilia testing (Factor V Leiden and prothrombin gene mutation):

Recommended Testing Scenarios:

You would qualify for testing if you had:

• Confirmed VTE (deep vein thrombosis or pulmonary embolism) at unusual sites (brain, abdominal veins)
• Confirmed VTE provoked by pregnancy, postpartum period, or oral contraceptives
• Confirmed VTE PLUS a first- or second-degree relative with diagnosed thrombophilia OR a first-degree relative with VTE at young age
• Low activated protein C resistance on lab testing

Testing May Be Considered If:

• You are contemplating pregnancy or estrogen use (birth control pills, hormone replacement) AND have a first-degree relative with VTE who is known to be homozygous (two copies) for Factor V Leiden 11
• You are a sibling of someone known to be homozygous for Factor V Leiden 11

Why Your Current Situation Doesn't Meet Criteria

Critical point: You had leg swelling but no confirmed clot. The guidelines specifically require documented VTE (confirmed blood clot) for most testing indications 11. Simply having a relative with Factor V Leiden, without your own confirmed clot, does not warrant testing in asymptomatic individuals 11.

The 2025 guidelines explicitly state that testing is "not recommended indiscriminately for all patients with VTE or for the general population" and that "it is generally not recommended to test asymptomatic minors as VTE rarely occurs before young adulthood even in the homozygous state" 1.

When Testing WOULD Change Management

Testing becomes valuable when results would actually alter clinical decisions 1:

• Contraceptive counseling: If you're considering estrogen-containing birth control and have a strong family history
• Pregnancy planning: Knowledge of high-risk genotypes (homozygous Factor V Leiden) influences thromboprophylaxis decisions during pregnancy 2
• Extended anticoagulation decisions: If you develop a confirmed VTE, knowing whether you're homozygous vs heterozygous affects treatment duration
• Risk counseling: For avoidable situations like extended travel, prolonged immobilization

What Tests Are Included

If testing becomes indicated, the standard panel includes 13:

• Factor V Leiden (F5 gene mutation)
• Prothrombin G20210A mutation (factor II)
• Antithrombin deficiency
• Protein C deficiency
• Protein S deficiency

Important caveat: MTHFR testing is NOT recommended by ACMG, ACOG, or British hematology societies, as it has no proven association with VTE risk 1.

Practical Next Steps

1. Confirm whether you actually had a DVT: If your leg swelling was never evaluated with ultrasound, and you're still concerned, get proper imaging to rule out current or residual clot

2. Document your family history precisely: Determine if your relative with Factor V Leiden is heterozygous (one copy) or homozygous (two copies), and whether they had VTE at a young age

3. Discuss with your provider if:

   • You're planning pregnancy
   • You're considering hormonal contraception
   • You develop a confirmed VTE in the future

4. Focus on modifiable risk reduction regardless of testing 4:

   • Avoid prolonged immobility during travel
   • Maintain healthy weight
   • Stay active
   • Discuss thromboprophylaxis for high-risk situations (surgery, hospitalization)

Common Pitfall to Avoid

Do not pursue testing "just to know" without a clear clinical indication where results would change management 56. Most people with Factor V Leiden heterozygosity never develop clots, and testing asymptomatic family members leads to unnecessary anxiety and potentially inappropriate interventions. The 2026 research confirms that "overestimation of the VTE risk and unnecessary use of heparin is an unsolved problem" 2.

Testing should only occur when a positive result would lead to specific preventive actions or treatment modifications that improve outcomes.